MDT-AP-1100
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 6
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.31644604
- umap2_2d
- 0.2403152
- umap1_3d
- -1.044779974
- umap2_3d
- -3.074465348
- umap3_3d
- -1.522369984
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- WNT_BETA_CATENIN_SIGNALING+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.220
- TGF_BETA_SIGNALING+0.180
- MYC_TARGETS_V1+0.150
- DNA_REPAIR+0.110
- MTORC1_SIGNALING+0.110
- APICAL_JUNCTION+0.070
- CHOLESTEROL_HOMEOSTASIS+0.070
- NOTCH_SIGNALING+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.410
- APOPTOSIS-0.390
- INTERFERON_GAMMA_RESPONSE-0.380
- ALLOGRAFT_REJECTION-0.360
- TNFA_SIGNALING_VIA_NFKB-0.330
- INFLAMMATORY_RESPONSE-0.310
- UV_RESPONSE_DN-0.310
- COMPLEMENT-0.300
- BILE_ACID_METABOLISM-0.260
- E2F_TARGETS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0360 | Med | Medulloblastoma | 0.808 |
| 2 | ERR2208948 | — | — | 0.795 |
| 3 | MDT-AP-0845 | Med | Medulloblastoma | 0.781 |
| 4 | MDT-AP-0756 | Med | Medulloblastoma | 0.769 |
| 5 | MDT-AP-1207 | Med | Medulloblastoma | 0.768 |
| 6 | MDT-AP-0604 | Med | Medulloblastoma | 0.761 |
| 7 | SRR12202489 | — | — | 0.755 |
| 8 | SRR5088894 | — | — | 0.749 |
| 9 | MNG147 | — | — | 0.748 |
| 10 | MDT-AP-0421 | Med | Medulloblastoma | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |